Explore Lumin Health's latest resources, discussion topics, and explorations into the safety and efficacy of ketamine therapy and Spravato (esketamine) treatments. Spravato (esketamine) was recently approved as the first and only mono-therapy for treatment-resistant depression*, so there is lots to explore by way of its mechanism of action, treatment protocols, qualitative experience and more. Lumin Health emphasizes in whole-person-centric care, working to not just treat symptoms of depression with ketamine and Spravato, but also manage lifestyle changes and health practices.
For in-depth explorations from our team of expert clinicians, we welcome you to visit our Clinical Reflections to learn a little bit more about what it's like to deliver innovative mental health treatment daily.
